Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Cardiovascular Systems management to meet virtually with Northland » 04:55
06/09/21
06/09
04:55
06/09/21
04:55
CSII

Cardiovascular Systems

$39.18 /

+0.385 (+0.99%)

Virtual Meeting to be…

Virtual Meeting to be held on June 9 hosted by Northland.

ShowHide Related Items >><<
CSII Cardiovascular Systems
$39.18 /

+0.385 (+0.99%)

CSII Cardiovascular Systems
$39.18 /

+0.385 (+0.99%)

05/25/21 Barclays
Barclays starts Medical Devices sector with Positive industry view
05/24/21 Barclays
Cardiovascular Systems initiated with an Equal Weight at Barclays
12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
CSII Cardiovascular Systems
$39.18 /

+0.385 (+0.99%)

  • 10
    Jun
Conference/Events
Cardiovascular Systems management to meet virtually with Northland » 11:47
06/08/21
06/08
11:47
06/08/21
11:47
CSII

Cardiovascular Systems

$38.74 /

-0.055 (-0.14%)

Virtual Meeting to be…

Virtual Meeting to be held on June 9 hosted by Northland.

ShowHide Related Items >><<
CSII Cardiovascular Systems
$38.74 /

-0.055 (-0.14%)

CSII Cardiovascular Systems
$38.74 /

-0.055 (-0.14%)

05/25/21 Barclays
Barclays starts Medical Devices sector with Positive industry view
05/24/21 Barclays
Cardiovascular Systems initiated with an Equal Weight at Barclays
12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
CSII Cardiovascular Systems
$38.74 /

-0.055 (-0.14%)

  • 10
    Jun
Initiation
Barclays starts Medical Devices sector with Positive industry view » 05:17
05/25/21
05/25
05:17
05/25/21
05:17
ABT

Abbott

$117.30 /

+0.2 (+0.17%)

, BSX

Boston Scientific

$42.81 /

+0.705 (+1.67%)

, EW

Edwards Lifesciences

$95.49 /

+1.28 (+1.36%)

, ZBH

Zimmer Biomet

$167.92 /

+0.61 (+0.36%)

, DXCM

DexCom

$355.47 /

+13.7 (+4.01%)

, PODD

Insulet

$256.89 /

+3.4 (+1.34%)

, CNMD

Conmed

$138.37 /

-0.655 (-0.47%)

, INMD

InMode

$82.83 /

+2.74 (+3.42%)

, BAX

Baxter

$82.75 /

-0.31 (-0.37%)

, BDX

Becton Dickinson

$243.46 /

-1.05 (-0.43%)

, MDT

Medtronic

$128.10 /

+0.84 (+0.66%)

, CSII

Cardiovascular Systems

$38.77 /

+0.23 (+0.60%)

, SYK

Stryker

$257.15 /

+1.49 (+0.58%)

, TNDM

TNDM

/

+

Barclays analyst Travis…

Barclays analyst Travis Steed last night initiated coverage on Medical Devices with a Positive industry view. "We could be at the beginning of another multi-year period of outperformance for medtech," Steed tells investors in a research note. Covid disrupted a decade of outperformance and years of accelerating revenue growth, and relative valuations are not pricing in the return of mid-single digit revenue growth levels, says the analyst. Steed prefers exposure to companies that will benefit as elective surgery comes back, and is Underweight names "that have done well but where growth moving forward could potentially become more challenging." His Overweight rated stocks are Abbott (ABT), Boston Scientific (BSX), Edwards Lifesciences (EW), Zimmer Biomet (ZBH), DexCom (DXCM), Insulet (PODD), Conmed (CNMD) and InMode (INMD). His Equal Weight rated names are Baxter (BAX), Becton Dickinson (BDX), Medtronic (MDT) and Cardiovascular Systems (CSII). Steed put Underweight ratings on Stryker (SYK) and Tandem Diabetes (TNDM).

ShowHide Related Items >><<
ZBH Zimmer Biomet
$167.92 /

+0.61 (+0.36%)

TNDM TNDM
/

+

SYK Stryker
$257.15 /

+1.49 (+0.58%)

PODD Insulet
$256.89 /

+3.4 (+1.34%)

MDT Medtronic
$128.10 /

+0.84 (+0.66%)

INMD InMode
$82.83 /

+2.74 (+3.42%)

EW Edwards Lifesciences
$95.49 /

+1.28 (+1.36%)

DXCM DexCom
$355.47 /

+13.7 (+4.01%)

CSII Cardiovascular Systems
$38.77 /

+0.23 (+0.60%)

CNMD Conmed
$138.37 /

-0.655 (-0.47%)

BSX Boston Scientific
$42.81 /

+0.705 (+1.67%)

BDX Becton Dickinson
$243.46 /

-1.05 (-0.43%)

BAX Baxter
$82.75 /

-0.31 (-0.37%)

ABT Abbott
$117.30 /

+0.2 (+0.17%)

ABT Abbott
$117.30 /

+0.2 (+0.17%)

05/24/21 Barclays
Abbott initiated with an Overweight at Barclays
04/29/21 Wells Fargo
Boston Scientific price target raised to $50 from $42 at Wells Fargo
04/15/21 Atlantic Equities
Atlantic Equities starts Abbott at Neutral
04/15/21 Atlantic Equities
Abbott initiated with a Neutral at Atlantic Equities
BSX Boston Scientific
$42.81 /

+0.705 (+1.67%)

05/24/21 Barclays
Boston Scientific initiated with an Overweight at Barclays
05/06/21 Raymond James
Abiomed could face new competition from Boston Scientific, says Raymond James
04/29/21 Truist
Boston Scientific price target raised to $50 from $42 at Truist
04/29/21 Canaccord
Boston Scientific price target raised to $49 from $44 at Canaccord
EW Edwards Lifesciences
$95.49 /

+1.28 (+1.36%)

05/24/21 Barclays
Edwards Lifesciences initiated with an Overweight at Barclays
04/21/21 Raymond James
Edwards Lifesciences price target raised to $101 from $96 at Raymond James
04/21/21 Wells Fargo
Edwards Lifesciences price target raised to $93 from $87 at Wells Fargo
04/21/21 Canaccord
Edwards Lifesciences price target raised to $103 from $94 at Canaccord
ZBH Zimmer Biomet
$167.92 /

+0.61 (+0.36%)

05/25/21 Barclays
Zimmer Biomet initiated with an Overweight at Barclays
05/11/21 JMP Securities
Zimmer Biomet price target raised to $195 from $180 at JMP Securities
05/05/21 Truist
Zimmer Biomet price target raised to $188 from $174 at Truist
05/05/21 Oppenheimer
Zimmer Biomet price target raised to $195 from $185 at Oppenheimer
DXCM DexCom
$355.47 /

+13.7 (+4.01%)

05/24/21 Barclays
DexCom initiated with an Overweight at Barclays
05/12/21 JPMorgan
JPMorgan sees four 'compelling' MedTech opportunities after selloff
04/30/21 Canaccord
DexCom price target raised to $455 from $445 at Canaccord
04/30/21 Citi
DexCom price target raised to $488 from $480 at Citi
PODD Insulet
$256.89 /

+3.4 (+1.34%)

05/24/21 Barclays
Insulet initiated with an Overweight at Barclays
05/07/21 Piper Sandler
Insulet price target lowered to $250 from $260 at Piper Sandler
04/01/21 SVB Leerink
Insulet upgraded to Outperform after diabetes deep dive at SVB Leerink
CNMD Conmed
$138.37 /

-0.655 (-0.47%)

05/24/21 Barclays
Conmed initiated with an Overweight at Barclays
04/29/21 Piper Sandler
Conmed price target raised to $160 from $145 at Piper Sandler
01/28/21 Piper Sandler
Conmed price target raised to $145 from $95 at Piper Sandler
09/30/20 Piper Sandler
Piper Sandler 'highly' recommends five names in Medical Technology
INMD InMode
$82.83 /

+2.74 (+3.42%)

05/24/21 Barclays
InMode initiated with an Overweight at Barclays
05/18/21 Needham
Needham starts InMode at Buy on 'leading' med tech margins, strong cash flow
05/18/21 Needham
InMode initiated with a Buy at Needham
05/06/21 Canaccord
InMode price target raised to $95 from $80 at Canaccord
BAX Baxter
$82.75 /

-0.31 (-0.37%)

05/24/21 Barclays
Baxter initiated with an Equal Weight at Barclays
04/30/21 Citi
Baxter price target raised to $98 from $94 at Citi
04/29/21 Piper Sandler
Baxter price target raised to $85 from $80 at Piper Sandler
03/26/21 JPMorgan
Baxter a 'stock to own' into earnings and beyond, says JPMorgan
BDX Becton Dickinson
$243.46 /

-1.05 (-0.43%)

05/24/21 Barclays
Becton Dickinson initiated with an Equal Weight at Barclays
04/05/21 Argus
Weaker demand for Covid testing solutions to weigh on BD, says Argus
04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/12/21 Wells Fargo
Wells Fargo sees only 'small chance' of positive FDA panel for Becton
MDT Medtronic
$128.10 /

+0.84 (+0.66%)

05/24/21 Barclays
Medtronic initiated with an Equal Weight at Barclays
04/15/21 Atlantic Equities
Atlantic Equities starts Medtronic at Overweight
04/15/21 Atlantic Equities
Medtronic initiated with an Overweight at Atlantic Equities
04/05/21 Citi
Citi opens positive catalyst watches on four medical supply stocks
CSII Cardiovascular Systems
$38.77 /

+0.23 (+0.60%)

05/24/21 Barclays
Cardiovascular Systems initiated with an Equal Weight at Barclays
12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
07/22/20
Fly Intel: Top five analyst initiations
SYK Stryker
$257.15 /

+1.49 (+0.58%)

05/24/21 Barclays
Stryker initiated with an Underweight at Barclays
04/28/21 Oppenheimer
Stryker price target raised to $273 from $240 at Oppenheimer
04/28/21 Wells Fargo
Stryker price target raised to $300 from $265 at Wells Fargo
04/28/21 Cowen
Stryker price target raised to $279 from $255 at Cowen
TNDM TNDM
/

+

05/24/21 Barclays
Tandem Diabetes initiated with an Underweight at Barclays
05/06/21 SVB Leerink
Tandem Diabetes price target raised to $102 from $95 at SVB Leerink
05/06/21 Oppenheimer
Tandem Diabetes price target raised to $135 from $130 at Oppenheimer
05/06/21 Piper Sandler
Tandem Diabetes remains a 'name to buy' after Q1 beat, says Piper Sandler
ZBH Zimmer Biomet
$167.92 /

+0.61 (+0.36%)

TNDM TNDM
/

+

SYK Stryker
$257.15 /

+1.49 (+0.58%)

PODD Insulet
$256.89 /

+3.4 (+1.34%)

MDT Medtronic
$128.10 /

+0.84 (+0.66%)

INMD InMode
$82.83 /

+2.74 (+3.42%)

EW Edwards Lifesciences
$95.49 /

+1.28 (+1.36%)

DXCM DexCom
$355.47 /

+13.7 (+4.01%)

CSII Cardiovascular Systems
$38.77 /

+0.23 (+0.60%)

CNMD Conmed
$138.37 /

-0.655 (-0.47%)

BSX Boston Scientific
$42.81 /

+0.705 (+1.67%)

BDX Becton Dickinson
$243.46 /

-1.05 (-0.43%)

BAX Baxter
$82.75 /

-0.31 (-0.37%)

ABT Abbott
$117.30 /

+0.2 (+0.17%)

  • 10
    Jun
BAX Baxter
$82.75 /

-0.31 (-0.37%)

ABT Abbott
$117.30 /

+0.2 (+0.17%)

ZBH Zimmer Biomet
$167.92 /

+0.61 (+0.36%)

SYK Stryker
$257.15 /

+1.49 (+0.58%)

PODD Insulet
$256.89 /

+3.4 (+1.34%)

INMD InMode
$82.83 /

+2.74 (+3.42%)

EW Edwards Lifesciences
$95.49 /

+1.28 (+1.36%)

DXCM DexCom
$355.47 /

+13.7 (+4.01%)

BSX Boston Scientific
$42.81 /

+0.705 (+1.67%)

BDX Becton Dickinson
$243.46 /

-1.05 (-0.43%)

BAX Baxter
$82.75 /

-0.31 (-0.37%)

ABT Abbott
$117.30 /

+0.2 (+0.17%)

ZBH Zimmer Biomet
$167.92 /

+0.61 (+0.36%)

MDT Medtronic
$128.10 /

+0.84 (+0.66%)

INMD InMode
$82.83 /

+2.74 (+3.42%)

EW Edwards Lifesciences
$95.49 /

+1.28 (+1.36%)

BSX Boston Scientific
$42.81 /

+0.705 (+1.67%)

ABT Abbott
$117.30 /

+0.2 (+0.17%)

Initiation
Cardiovascular Systems initiated with an Equal Weight at Barclays » 19:11
05/24/21
05/24
19:11
05/24/21
19:11
CSII

Cardiovascular Systems

$38.77 /

+0.23 (+0.60%)

Barclays analyst Travis…

Barclays analyst Travis Steed initiated coverage of Cardiovascular Systems with an Equal Weight rating.

ShowHide Related Items >><<
CSII Cardiovascular Systems
$38.77 /

+0.23 (+0.60%)

CSII Cardiovascular Systems
$38.77 /

+0.23 (+0.60%)

12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
07/22/20
Fly Intel: Top five analyst initiations
07/22/20 Northland
Cardiovascular Systems initiated with an Outperform at Northland
CSII Cardiovascular Systems
$38.77 /

+0.23 (+0.60%)

  • 10
    Jun
Over a month ago
Earnings
Cardiovascular Systems sees Q4 revenue $67M-$70M, consensus $69.78M.  16:52
05/06/21
05/06
16:52
05/06/21
16:52
CSII

Cardiovascular Systems

$38.99 /

-0.6 (-1.52%)

 
ShowHide Related Items >><<
CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
07/22/20
Fly Intel: Top five analyst initiations
07/22/20 Northland
Cardiovascular Systems initiated with an Outperform at Northland
CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

  • 10
    Jun
Earnings
Cardiovascular Systems reports Q3 EPS (15c), consensus (10c) » 16:51
05/06/21
05/06
16:51
05/06/21
16:51
CSII

Cardiovascular Systems

$38.99 /

-0.6 (-1.52%)

Reports Q3 revenue…

Reports Q3 revenue $63.3M, consensus $63.12M. CEO Scott Ward says: "Third quarter revenues increased 3.4% to $63.3 million and were led by our coronary franchise, due to strong procedure volume domestically, increased sales of procedure support products, and growing adoption of orbital atherectomy internationally. Peripheral revenues were flat as patients with claudication continued to defer evaluation and treatment. Office-based labs purchased nearly one-half of our peripheral unit volume during the quarter demonstrating that an increased number of complex peripheral procedures were performed outside the hospital. Throughout the pandemic, we have seen the OBL become another viable option for complex procedures, which we expect to continue even as the pandemic subsides. As we head into our fourth quarter, we believe the majority of markets we serve have either returned to pre-Covid procedure levels or are poised to do so in the very near future."

ShowHide Related Items >><<
CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
07/22/20
Fly Intel: Top five analyst initiations
07/22/20 Northland
Cardiovascular Systems initiated with an Outperform at Northland
CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

  • 10
    Jun
Hot Stocks
Cardiovascular Systems enters investment, acquisition option deal with CarePICS » 07:05
04/08/21
04/08
07:05
04/08/21
07:05
CSII

Cardiovascular Systems

$36.33 /

-1.55 (-4.09%)

Cardiovascular Systems…

Cardiovascular Systems announced that it has completed a minority investment and entered into an acquisition option agreement with CarePICS, a telehealth company offering a virtual care platform designed to improve the outcomes of patients suffering from peripheral artery disease, or PAD, critical limb ischemia, or CLI, and lower extremity wounds. PAD is a progressive disease affecting at least 18M Americans. CarePICS is the first technology-enabled care management tool specifically designed for the treatment of patients with this disease. Through a secure iOS, Android and Web platform, CarePICS enables podiatrists, nursing facilities, home health agencies, wound care providers and primary care physicians to capture patient information, wound images and measurements. The platform's features can also be utilized by physicians after vascular treatment to coordinate, follow and support wound healing progress.

ShowHide Related Items >><<
CSII Cardiovascular Systems
$36.33 /

-1.55 (-4.09%)

CSII Cardiovascular Systems
$36.33 /

-1.55 (-4.09%)

12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
07/22/20
Fly Intel: Top five analyst initiations
07/22/20 Northland
Cardiovascular Systems initiated with an Outperform at Northland
CSII Cardiovascular Systems
$36.33 /

-1.55 (-4.09%)

  • 10
    Jun
Hot Stocks
Cardiovascular Systems acquires peripheral support catheters from WavePoint » 09:01
03/22/21
03/22
09:01
03/22/21
09:01
CSII

Cardiovascular Systems

$40.51 /

+0.21 (+0.52%)

Cardiovascular Systems…

Cardiovascular Systems announced that it has acquired a line of peripheral support catheters from WavePoint Medical, LLC. In addition, as part of this transaction, WavePoint will also develop a portfolio of specialty catheters used in the treatment of chronic total occlusions and complex percutaneous coronary intervention procedures for CSI. Commercial availability of these specialty catheters is anticipated in CSI's fiscal year ending June 30, 2023. Scott R. Ward, Chairman, President and CEO of CSI, said, "With the acquisition of these peripheral support catheters, CSI will soon offer a complete portfolio of products for the treatment of peripheral artery disease, including atherectomy, balloon catheters, guidewires, support catheters and embolic protection. In coronary, the successful development of a portfolio of CTO products will expand our existing offering of coronary support products. Together, these new products advance our ability to help physicians improve outcomes for patients undergoing complex peripheral and coronary interventions."

ShowHide Related Items >><<
CSII Cardiovascular Systems
$40.51 /

+0.21 (+0.52%)

CSII Cardiovascular Systems
$40.51 /

+0.21 (+0.52%)

12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
07/22/20
Fly Intel: Top five analyst initiations
07/22/20 Northland
Cardiovascular Systems initiated with an Outperform at Northland
CSII Cardiovascular Systems
$40.51 /

+0.21 (+0.52%)

  • 10
    Jun
Over a quarter ago
Earnings
Cardiovascular Systems sees Q3 revenue $60M-$65M, consensus $69.27M » 16:13
02/03/21
02/03
16:13
02/03/21
16:13
CSII

Cardiovascular Systems

$43.11 /

+0.075 (+0.17%)

Sees Q3 gross profit as a…

Sees Q3 gross profit as a percentage of revenues in the 77% to 78% range; Operating expenses in a range of $52M-$54M; Net loss in a range of $3.5M-$6.0M; and near neutral Adjusted EBITDA.

ShowHide Related Items >><<
CSII Cardiovascular Systems
$43.11 /

+0.075 (+0.17%)

CSII Cardiovascular Systems
$43.11 /

+0.075 (+0.17%)

12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
07/22/20
Fly Intel: Top five analyst initiations
07/22/20 Northland
Cardiovascular Systems initiated with an Outperform at Northland
CSII Cardiovascular Systems
$43.11 /

+0.075 (+0.17%)

  • 10
    Jun
Earnings
Cardiovascular Systems reports Q2 EPS (0c), consensus (6c) » 16:11
02/03/21
02/03
16:11
02/03/21
16:11
CSII

Cardiovascular Systems

$43.07 /

+0.035 (+0.08%)

Reports Q2 revenue…

Reports Q2 revenue $64.2M, consensus $65.51M. Scott Ward, Chairman, President and CEO, said: "Today we reported second quarter revenues of $64.2 million, representing a sequential quarterly improvement of 6%. The surge in new COVID cases and increased ICU demand began negatively impacting our procedures during the final weeks of December and as a result our revenue finished slightly below the midpoint of our guidance range. Considering the unprecedented spike in hospital admissions, we are really pleased with these results and proud of our team's focused support of our customers and patients under these extreme conditions."

ShowHide Related Items >><<
CSII Cardiovascular Systems
$43.07 /

+0.035 (+0.08%)

CSII Cardiovascular Systems
$43.07 /

+0.035 (+0.08%)

12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
07/22/20
Fly Intel: Top five analyst initiations
07/22/20 Northland
Cardiovascular Systems initiated with an Outperform at Northland
CSII Cardiovascular Systems
$43.07 /

+0.035 (+0.08%)

  • 10
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.